Results 11 to 20 of about 97,221 (328)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

The Journal of Headache and Pain, 2019
Background and aim Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor ...
Simona Sacco, Lars Bendtsen, Messoud Ashina, Uwe Reuter, Gisela Terwindt, Dimos-Dimitrios Mitsikostas, Paolo Martelletti   +6 more
doaj   +2 more sources

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

Brain Sciences, 2020
Cluster headache (CH) is a severe primary headache with a prevalence of 1/1000 individuals, and a predominance in men. Calcitonin gene-related peptide (CGRP) is a potent vasodilator, originating in trigeminal neurons and has a central role in CH ...
Andrea Carmine Belin, Caroline Ran, Lars Edvinsson   +2 more
doaj   +2 more sources

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

The Journal of Headache and Pain, 2019
Background Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden.
Cindy Tiseo, Raffaele Ornello, Francesca Pistoia, Simona Sacco   +3 more
doaj   +2 more sources

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine [PDF]

New England Journal of Medicine, 2004
Background: Calcitonin gene–related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks.
Diener, H.-C., Goadsby, P.J., Hall, D., Husstedt, I.G., Lesko, L.M., Meier, U., Olesen, J., Pollentier, S.   +7 more
core   +2 more sources

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

The Journal of Headache and Pain, 2022
Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world
S. Sacco, F. Amin, M. Ashina, L. Bendtsen, C. Deligianni, R. Gil-Gouveia, Z. Katsarava, A. Maassenvandenbrink, P. Martelletti, D. Mitsikostas, R. Ornello, U. Reuter, M. Sanchez-del-Rio, A. Sinclair, G. Terwindt, D. Uluduz, J. Versijpt, C. Lampl   +17 more
semanticscholar   +1 more source

Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine

European Journal of Neurology, 2023
The aim was to evaluate the effect of anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies on depressive symptoms in subjects with migraine and to determine whether depressive symptoms predict treatment response.
Simone de Vries Lentsch, Britt W. H. van der Arend, I. de Boer, E. V. van Zwet, A. Maassenvandenbrink, Gisela M. Terwindt   +5 more
semanticscholar   +1 more source

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine

Frontiers in Physiology, 2022
The development of small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) and of monoclonal antibodies targeting the CGRP system has been a major advance in the management of migraine.
P. Holzer, U. Holzer‐Petsche
semanticscholar   +1 more source

Implantable Electrical Stimulation at Dorsal Root Ganglions Accelerates Osteoporotic Fracture Healing via Calcitonin Gene‐Related Peptide

Advancement of science, 2021
The neuronal engagement of the peripheral nerve system plays a crucial role in regulating fracture healing, but how to modulate the neuronal activity to enhance fracture healing remains unexploited.
Jie Mi, Jian-Kun Xu, Zhi Yao, Hao Yao, Ye Li, X. He, Bingyang Dai, Li Zou, Wenxue Tong, Xiaotian Zhang, Peijie Hu, Y. Ruan, Ning Tang, Xia Guo, Jie Zhao, Junhui He, L. Qin   +16 more
semanticscholar   +1 more source

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Headache, 2021
To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant.
Abhijeet Jakate, A. Blumenfeld, R. Boinpally, M. Butler, Lisa M. Borbridge, Janette Contreras-De Lama, D. McGeeney, A. Periclou, R. Lipton   +8 more
semanticscholar   +1 more source

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

Headache, 2021
Calcitonin gene‐related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the patterns which
A. Kawata, N. Shah, J. Poon, S. Shaffer, S. Sapra, T. Wilcox, Shweta Shah, S. Tepper, D. Dodick, R. Lipton   +9 more
semanticscholar   +1 more source